ASX biotech share surges 20% higher on COVID-19 drug trial

The Mesoblast Limited (ASX: MSB) share price is surging higher today in response to news of a formal coronavirus drug trial.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price is surging higher today in response to news of a coronavirus drug trial. 

This morning, Mesoblast informed the ASX that it will begin formal trials for a product to treat patients suffering from COVID-19 within the coming weeks.

What trials will Mesoblast be conducting?

Mesoblast has announced that its allogeneic mesenchymal stem cell (MSC) product, remestemcel-L, will be evaluated in a randomised, placebo-controlled trial. The trial will be conducted as a private-public partnership in conjunction with the Cardiothoracic Surgical Trials Network (CTSN) on 240 patients with acute respiratory distress syndrome (ARDS) caused by COVID-19.

Commencement of the trial follows Mesoblast's approved application for an Investigational New Drug (IND) from the US Food and Drug Administration (FDA) earlier this week. With the coronavirus pandemic moving quickly in the US, the FDA was quick to approve Mesoblast's investigational study as the product is already in a number of clinical trials for inflammatory conditions.

How does Mesoblast's product help patients with COVID-19?

The COVID-19 virus has a detrimental impact on the lungs of patients by initiating an overproduction of immune cells. The virus creates a 'cytokine storm' which results in immune cells flooding the lungs, causing substantial inflammation and a build-up of fluid that can result in death. As a result, patients suffer from ARDS and are admitted to intensive care units to receive oxygen ventilation. According to the company's update, the mortality rate of patients with ARDS as a result of COVID-19 is as high as 80%.

Mesoblast's remestemcel-L product is design to counteract the inflammatory process by neutralising the production of pro-inflammatory cytokines and promoting the production of anti-inflammatory cytokines.  Remestemcel-L was already in a number of other clinical trials targetted at reducing inflammatory conditions on patients with steroid-refractory acute graft versus host disease (aGVHD).

Foolish takeaway

Mesoblast is a world leader in developing regenerative medicines for inflammatory diseases and has prided itself on innovation in stem cell research. The company has used its cell therapy technology to establish a broad portfolio of commercial products and has a large pipeline of therapies in late-stage development and testing.

If proven effective against ARDS in COVID-19 patients, the product could save thousands and thousands of lives and would be monumental for medical science and biotechnology in Australia.

The Mesoblast share price has surged more than 55% since receiving approval from the FDA earlier this week and is currently trading 20.16% higher today, having hit an intra-day high of $2.21.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »